R. T. Chacko

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

P. K. Julka, R. T. Chacko, S. Nag et al. · British Journal of Cancer · 2008 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC)

Pankaj Bhargava, B. Esteves, Dmitry Nosov et al. · Journal of Clinical Oncology · 2009 · 31 citations

Medicine, Oncology, Pharmacotherapy +16

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

Pankaj Bhargava, B. Esteves, Mohammed Al-Adhami et al. · Journal of Clinical Oncology · 2010 · 24 citations

Medicine, Oncology, Pharmacotherapy +14

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).

D. Nosov, Pankaj Bhargava, W. B. Esteves et al. · Journal of Clinical Oncology · 2011 · 19 citations

Medicine, Oncology, Pharmacotherapy +17

Primary mediastinal synovial sarcoma with transdiaphragmatic extension presenting as a pericardial effusion.

Anila Korula, Amit Shah, Madhu Andrew Philip et al. · PubMed · 2009 · 18 citations

Medicine, Oncology, Pathology +17